<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03471065</url>
  </required_header>
  <id_info>
    <org_study_id>2018-03</org_study_id>
    <nct_id>NCT03471065</nct_id>
  </id_info>
  <brief_title>The SAPIEN 3 Ultra System in Intermediate Risk Patients With Symptomatic, Severe Aortic Stenosis</brief_title>
  <official_title>A Prospective, Single-arm, Multicenter Study of the SAPIEN 3 Ultra System in Intermediate Risk Patients With Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will confirm the procedural safety and performance of the SAPIEN 3 Ultra System in&#xD;
      subjects with severe, calcific AS who are at intermediate operative risk for standard aortic&#xD;
      valve replacement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Actual">December 23, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>SAPIEN 3 Ultra System</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>Day 0</time_frame>
    <description>Defined as freedom from all of the following at exit from the procedure room:&#xD;
Mortality&#xD;
Conversion to surgery&#xD;
Moderate or severe paravalvular regurgitation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Vascular Complications</measure>
    <time_frame>Discharge</time_frame>
    <description>Number of patients with major vascular complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve Migration or Embolization</measure>
    <time_frame>Discharge</time_frame>
    <description>Number of patients with valve migration or embolization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Transcatheter Aortic Valve Replacement (TAVR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV</intervention_name>
    <description>Patients will be implanted with the SAPIEN 3 Ultra THV (20, 23 and 26 mm) or SAPIEN 3 THV (29 mm) using the SAPIEN 3 Ultra Delivery System.</description>
    <arm_group_label>Transcatheter Aortic Valve Replacement (TAVR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Severe, calcific aortic stenosis meeting the following transthoracic echocardiogram&#xD;
             criteria:&#xD;
&#xD;
               -  Aortic valve area ≤ 1.0 cm2 OR aortic valve area index ≤ 0.6 cm2/m2&#xD;
&#xD;
               -  Jet velocity ≥ 4.0 m/s OR mean gradient ≥ 40 mmHg&#xD;
&#xD;
          2. New York Heart Association functional class ≥ II&#xD;
&#xD;
          3. Judged by the Heart Team to be at intermediate risk for open surgical therapy&#xD;
&#xD;
          4. The subject has been informed of the nature of the study, agrees to its provisions and&#xD;
             has provided written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Native aortic annulus size unsuitable for available THV sizes on 3D imaging analysis&#xD;
&#xD;
          2. Aortic valve is unicuspid, bicuspid or non-calcified&#xD;
&#xD;
          3. Pre-existing mechanical or bioprosthetic valve in any position.&#xD;
&#xD;
          4. Severe aortic regurgitation (&gt; 3+)&#xD;
&#xD;
          5. Severe mitral regurgitation (&gt; 3+) or ≥ moderate stenosis&#xD;
&#xD;
          6. Ventricular dysfunction with left ventricular ejection fraction &lt; 30%&#xD;
&#xD;
          7. Cardiac imaging evidence of intracardiac mass, thrombus or vegetation&#xD;
&#xD;
          8. Evidence of an acute myocardial infarction ≤ 30 days before the valve implant&#xD;
             procedure&#xD;
&#xD;
          9. Subjects with planned concomitant ablation for atrial fibrillation&#xD;
&#xD;
         10. Hypertrophic cardiomyopathy with obstruction&#xD;
&#xD;
         11. Coronary anatomy that increases the risk of coronary artery obstruction post-TAVR&#xD;
&#xD;
         12. Complex coronary artery disease:&#xD;
&#xD;
               1. Unprotected left main coronary artery&#xD;
&#xD;
               2. SYNTAX score &gt; 32&#xD;
&#xD;
               3. Heart Team assessment that optimal revascularization cannot be performed&#xD;
&#xD;
         13. Iliofemoral vessel characteristics that would preclude safe placement of the&#xD;
             introducer sheath&#xD;
&#xD;
         14. Significant abdominal or thoracic aortic disease that would preclude safe passage of&#xD;
             the delivery system&#xD;
&#xD;
         15. Active bacterial endocarditis within 180 days of the valve implant procedure&#xD;
&#xD;
         16. Stroke or transient ischemic attack within 90 days of the valve implant procedure&#xD;
&#xD;
         17. Symptomatic carotid or vertebral artery disease or successful treatment of carotid&#xD;
             stenosis within 30 days of the valve implant procedure&#xD;
&#xD;
         18. Severe lung disease (Forced Ejection Volume 1 &lt; 50% predicted) or currently on home&#xD;
             oxygen&#xD;
&#xD;
         19. Severe pulmonary hypertension&#xD;
&#xD;
         20. Hemodynamic or respiratory instability requiring inotropic support, mechanical&#xD;
             ventilation or mechanical heart assistance within 30 days of the valve implant&#xD;
             procedure&#xD;
&#xD;
         21. History of cirrhosis or any active liver disease&#xD;
&#xD;
         22. Renal insufficiency and/or renal replacement therapy at the time of screening&#xD;
&#xD;
         23. Leukopenia, anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy or&#xD;
             hypercoagulable states&#xD;
&#xD;
         24. Inability to tolerate or condition precluding treatment with antithrombotic therapy&#xD;
             during or after the valve implant procedure&#xD;
&#xD;
         25. Absolute contraindications or allergy to iodinated contrast that cannot be adequately&#xD;
             treated with pre-medication&#xD;
&#xD;
         26. Significant frailty as determined by the Heart Team&#xD;
&#xD;
         27. Subject refuses blood products&#xD;
&#xD;
         28. Body mass index &gt; 50 kg/m2&#xD;
&#xD;
         29. Estimated life expectancy &lt; 24 months&#xD;
&#xD;
         30. Positive urine or serum pregnancy test in female subjects of childbearing potential&#xD;
&#xD;
         31. Currently participating in an investigational drug or another device study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Webb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Paul's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2018</study_first_posted>
  <results_first_submitted>December 22, 2020</results_first_submitted>
  <results_first_submitted_qc>December 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 19, 2021</results_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter</keyword>
  <keyword>Transcatheter Valve Replacement</keyword>
  <keyword>SAPIEN 3 Ultra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be available to other researchers.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03471065/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Transcatheter Aortic Valve Replacement (TAVR)</title>
          <description>SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV: Patients will be implanted with the SAPIEN 3 Ultra THV (20, 23 and 26 mm) or SAPIEN 3 THV (29 mm) using the SAPIEN 3 Ultra Delivery System.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transcatheter Aortic Valve Replacement (TAVR)</title>
          <description>SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV: Patients will be implanted with the SAPIEN 3 Ultra THV (20, 23 and 26 mm) or SAPIEN 3 THV (29 mm) using the SAPIEN 3 Ultra Delivery System.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.5" spread="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Society of Thoracic Surgeons (STS) Score</title>
          <description>The Society of Thoracic Surgeons (STS) Score measures patient risk of mortality or morbidity at the time of cardiovascular surgery on a scale that ranges from 0% to 100%, with higher numbers indicating greater risk of operative mortality.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.6" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association (NYHA) Class Grouped</title>
          <description>New York Heart Association (NYHA) functional classification of heart failure is based on how much a patient is limited during physical activity. The rating ranges from I-IV. I = no limitations of physical activity; II = slight limitations of physical activity, ordinary physical activity results in fatigue, palpitation, shortness of breath; III = marked limitations of physical activity, less than ordinary activity causes fatigue, palpitation, or shortness of breath; IV = unable to carry on any physical activity without discomfort, symptoms of heart failure at rest.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Class I/II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class III/IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Procedural Success</title>
        <description>Defined as freedom from all of the following at exit from the procedure room:&#xD;
Mortality&#xD;
Conversion to surgery&#xD;
Moderate or severe paravalvular regurgitation</description>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transcatheter Aortic Valve Replacement (TAVR)</title>
            <description>SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV: Patients will be implanted with the SAPIEN 3 Ultra THV (20, 23 and 26 mm) or SAPIEN 3 THV (29 mm) using the SAPIEN 3 Ultra Delivery System.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Defined as freedom from all of the following at exit from the procedure room:&#xD;
Mortality&#xD;
Conversion to surgery&#xD;
Moderate or severe paravalvular regurgitation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Vascular Complications</title>
        <description>Number of patients with major vascular complications</description>
        <time_frame>Discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transcatheter Aortic Valve Replacement (TAVR)</title>
            <description>SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV: Patients will be implanted with the SAPIEN 3 Ultra THV (20, 23 and 26 mm) or SAPIEN 3 THV (29 mm) using the SAPIEN 3 Ultra Delivery System.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Vascular Complications</title>
          <description>Number of patients with major vascular complications</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Valve Migration or Embolization</title>
        <description>Number of patients with valve migration or embolization</description>
        <time_frame>Discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transcatheter Aortic Valve Replacement (TAVR)</title>
            <description>SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV: Patients will be implanted with the SAPIEN 3 Ultra THV (20, 23 and 26 mm) or SAPIEN 3 THV (29 mm) using the SAPIEN 3 Ultra Delivery System.</description>
          </group>
        </group_list>
        <measure>
          <title>Valve Migration or Embolization</title>
          <description>Number of patients with valve migration or embolization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30-days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Transcatheter Aortic Valve Replacement (TAVR)</title>
          <description>SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV: Patients will be implanted with the SAPIEN 3 Ultra THV (20, 23 and 26 mm) or SAPIEN 3 THV (29 mm) using the SAPIEN 3 Ultra Delivery System.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edwards THV Clinical Affairs</name_or_title>
      <organization>Edwards Lifesciences</organization>
      <phone>949-250-2500</phone>
      <email>THV_CT.gov@edwards.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

